Learn More
Methotrexate, MP Biomedicals™
Description
Methotrexate is actively transported into cells by the folate transporter. In the cell, it is converted to a high molecular weight polyglutamate metabolite by folypolyglutamate synthase that, in turn, binds to dihydrofolate reductase and inhibits its activity. Methotrexate-polyglutamate is degraded intracellularly by gamma-glutamyl hydrolase.
Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis.
- Potent inhibitor of dihydrofolate reductase in DHFR-based protein expression systems
- Anti-cancer agent used in antitumor studies
- Effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites
- Shows immunosuppressive effects, e.g. in rheumatoid arthritis

Specifications
Specifications
Melting Point | 185°C to 204°C |
Boiling Point | 184°C to 204°C (monohydrate decomposition) |
Quantity | 10 mg |
Solubility Information | Soluble in alkaline solutions with decomposition.Insoluble in water, ethanol, chloroform and ether. |
Optical Rotation | 19–24° |
Formula Weight | 454.4 |
Grade | USP |
Physical Form | Powder |
Safety and Handling
Recommended Storage | 4°C |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.